PriceTargets.com logo

EPA:DIM - Sartorius Stedim Biotech Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: €400.00
  • Forecasted Upside: 8.99 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
€367.00 As of 01/14/2022 01:00 AM ET
▼ -19.9 (-5.14%)

This chart shows the closing price for DIM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sartorius Stedim Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DIM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DIM

Analyst Price Target is €400.00
▲ +8.99% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Sartorius Stedim Biotech in the last 3 months. The average price target is €400.00, with a high forecast of €400.00 and a low forecast of €400.00. The average price target represents a 8.99% upside from the last price of €367.00.

This chart shows the closing price for DIM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Sartorius Stedim Biotech.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/19/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/17/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/29/2021JPMorgan Chase & Co.Set Price TargetBuy€400.00
5/2/2018UBS GroupSet Price TargetNeutral€135.00
4/25/2018Deutsche Bank AktiengesellschaftSet Price TargetNeutral€120.00
4/24/2018Kepler Capital MarketsSet Price TargetNeutral€78.00
4/24/2018Berenberg BankSet Price TargetNeutral€110.00
4/24/2018CommerzbankSet Price TargetNeutral€76.00
4/18/2018Deutsche Bank AktiengesellschaftSet Price TargetNeutral€120.00
4/17/2018Warburg ResearchSet Price TargetBuy€141.00
(Data available from 1/17/2017 forward)

News Sentiment Rating

0.22 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/17/2022

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Sartorius Stedim Biotech logo
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; single-use and reusable hollow-fiber membrane devices, as well as presterilized assemblies for cell and gene therapy applications; and cell harvesting and various other solutions for intensified bioprocesses. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Read More

Today's Range

Now: €367.00
Low: €363.90
High: €382.10

50 Day Range

MA: €465.85
Low: €386.90
High: €515.40

52 Week Range

Now: €367.00

Volume

95,356 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Sartorius Stedim Biotech?

The following Wall Street analysts have issued reports on Sartorius Stedim Biotech in the last year: JPMorgan Chase & Co..
View the latest analyst ratings for DIM.

What is the current price target for Sartorius Stedim Biotech?

1 Wall Street analysts have set twelve-month price targets for Sartorius Stedim Biotech in the last year. Their average twelve-month price target is €400.00, suggesting a possible upside of 9.0%. JPMorgan Chase & Co. has the highest price target set, predicting DIM will reach €400.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of €400.00 for Sartorius Stedim Biotech in the next year.
View the latest price targets for DIM.

What is the current consensus analyst rating for Sartorius Stedim Biotech?

Sartorius Stedim Biotech currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DIM will outperform the market and that investors should add to their positions of Sartorius Stedim Biotech.
View the latest ratings for DIM.

What other companies compete with Sartorius Stedim Biotech?

Other companies that are similar to Sartorius Stedim Biotech include 4DMedical, Adherium, ADM Tronics Unlimited, Allegra Orthopaedics, Analytica, AnteoTech, Anteris Technologies, Asensus Surgical, Atomo Diagnostics, AVITA Medical, Azure Healthcare Limited (AZV.AX), Cannabix Technologies, CleanSpace, Cochlear and Cochlear.

How do I contact Sartorius Stedim Biotech's investor relations team?

The company's listed phone number is 33 4 42 84 56 00. The official website for Sartorius Stedim Biotech is www.sartorius.com.